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Defects in protein glycosylation can have a dramatic impact
on eukaryotic cells and is associated with mental and develop-
mental pathologies in humans. The studies outlined below illus-
trate how a basic biochemical problem in the mechanisms of
protein glycosylation, specifically substrate transporters of
nucleotide sugars, including ATP and 3-phosphoadenyl-5-
phosphosulfate (PAPS), in the membrane of the Golgi appa-
ratus and endoplasmic reticulum, expanded into diverse bio-
logical systems from mammals, including humans, to yeast,
roundworms, and protozoa. Using these diverse model systems
allowedmy colleagues andme to answer fundamental biological
questions that enabled us to formulate far-reaching hypotheses
and expanded our knowledge of human diseases caused bymal-
functions in the metabolic processes involved.
My early years
As you can see, I have a Spanish first name and German-
Jewish last name. The origin of my name is rooted in simple
history. My parents were born in Silesia, when it was part of
Germany.My fatherwas a judge, which at that time inGermany
was an academic career, separate from becoming an attorney.
My mother was among the first students to study social work,
which then had a strong nursing component. In 1933, with
Hitler’s ascent to power, my father, along with other Jewish
judges, was thrown out of the German court system. This was
an unjust act, as Germany had agreed after World War I,
because parts of Silesia had been in Poland, not to discriminate
in any way toward minorities in that region until 1938. Legal
action was taken, and someone appealed to an international
court, claiming that minorities also included Jews, and surpris-
ingly, Hitler abided by this.
My fatherwent back towork, but everyone knew that by 1938
this would end. Toward the end of that year, my parents moved
to Berlin to prepare for their departure to Chile, where fortu-
nately, my father’s brother and his family had earlier immi-
grated. A few days after Kristallnacht (November 8, 1938), my
father was detained and sent to a concentration camp.
Although the stay was short, it was a life-changing experience
for him. Fortunately, at that time, if one had an exit visa to leave
Germany, one was freed from the camp and allowed to leave
Germany. Thus, my parents and my sister left Germany for
Chile in March 1939. A German judge could not really find an
adequate job in Chile, so my father worked odd jobs as an
accountant whilemymother’s nursing training helped the fam-
ily survive. A few years later, I was born in a country which, as
stated in its national anthem state, “is an asylum against
oppression.”
My parents were eking out a living when my father died in a
skiing accident. My mother was left with my sister, age 16, and
me, age 4. When the time came for me to attend kindergarten,
I was sent to a Swiss school in Santiago where I stayed until
graduating from high school. My mother thought that the dis-
cipline and languages offered at the school would be good for
me. In addition to Spanish, we learned German, English, and
French. These languages would be of great help to me when I
worked on my Ph. D. degree because, as part of the require-
ments for the degree, we had to translate scientific papers from
German and French into English. Did they help me later in my
scientific career? Not really!
University in Chile
In high school, I found humanities very easy, while sciences
required more effort. In Chile, at that time, most university
studies were free, but very competitive to get into. One first had
to take a general exam, called “Bachillerato,” to attend a univer-
sity, and then another exam to enter the specific school within
the university you wanted to attend. I chose to study biochem-
istry because I did not like pure chemistry or pure biology.
However, I did not even know what biochemistry really was! In
Chile at that time, a student entered directly from high school
into a professional school, with the risk that if you did not like
the particular choice, you could not transfer to another school
without starting from scratch. For the first 3 years working
toward my professional degree as a “Biochemist,” the seven
other students and I studiedwith students in theChemistry and
Pharmacy programs, while for the last 2 years, we studied in
separate programs.
One could not take a final exam in each course without a
“pass,” an average C grade or 12 points. This scale was absolute
with God receiving the top grade, 21 points, the professor, 18
points, and the rest of us mortals scoring between 12 and 18
points. Once you were allowed to take the final exam in a
course, you could, of course, fail again. If you failed a course, you
hadone chance to retake the exam, and if you failed again or had
more than one course without a pass for the final, you had to
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retake these courses again the next year and could not enroll in
any subject for the following year curriculum. This was clearly a
total waste of taxpayer money and contributed to the fact that
only eight students, myself included, of the initial 100 finished
the program in the minimum of 5 years! Unfortunately, the
school wouldn’t rank us, so our transcripts weren’t particularly
impressive.
Graduate school in the U.S.A.
At that time, there were no graduate programs in sciences in
Chile. For family reasons, I then enrolled at Rutgers in an MS
program in Nutrition with a minor in Biochemistry. The grad-
uate Biochemistry courses were easy compared with the
courses I had in Chile. For my MS thesis, I worked on lipids of
the avian brain with few interesting and publishable results.
This experience taughtme a life lesson about the importance of
choosing a good thesis project and would serve me well as an
advisor for my students.
Thereafter, I entered the Ph. D. program in the Biochemistry
Division of the Chemistry Department at the University of Illi-
nois-Urbana. The department was then ranked as one of the
highest in the country, and during the first year I took courses in
physical chemistry, biophysical chemistry, and organic chem-
istry. The courseswere so difficult forme that at times I thought
I wouldn’t survive and that I would have to return to Chile with
a Master’s degree, which I rationalized wouldn’t be that bad. I
distinctly remember thinking twice about whether or not to
renew a subscription to a magazine as there was a good chance
Iwould not be around to receive new issues! In the end, I did just
fine. I hadn’t taken into account that I would be graded on a
curve. In one case, my organic chemistry professor gave back
seven exams (one of which was mine) out of approximately
60, saying that there was no point in returning the rest of the
exams! I looked at mine, and I had received a score of 4/20. I
folded my exam and kept very quiet. Only much later did I find
out, to my surprise, that the exams he had not returned had
scored 0/20.
As mentioned before, during my MS thesis at Rutgers, I had
become interested in lipids and sought out Professor Herb
Carter for my Ph. D. thesis. His area of research was the chem-
istry of sphingolipids, which are lipids containing the long-
chain base sphingosine (Fig. 1). He was the head of the Chem-
istry Department (with 60 facultymembers), and I was told that
he wasn’t taking any more students. After listening to the other
faculty members’ projects, I became rather discouraged and
told one of the younger professors that I was thinking of per-
haps leaving the department. He told me to talk to Herb again,
and he was sure Herb would take me as a student. I prepared a
long speech of why I wanted to work with him, and as soon as I
saw him and started my reasoning, he told me, “Ok, I’ll tell ’so
and so’ to give you a desk inmy laboratory.” I had over-prepared
my speech, but in retrospect, working in Herb’s lab was one of
the best decisions in my scientific career.
My first project was to describe which sphingosine bases
occurred in the beef kidney. GLC was one of the preferred
methods to identify long-chain bases based on their relative
mobility onGLC columns. Onewould also routinely reduce the
long-chain bases’ double bonds with hydrogen and palladium
and analyze the corresponding changes in mobility on the GLC
columns. After some routine analyses, I found that before and
after catalytic hydrogenation it appeared that one peak still
migrated in the position of C18 sphingosine, which, of course,
has a double bond and should have been completely reduced to
C18 sphinganine. At some point, I decided to do a control to see
whether, in my hands, standard C18 sphingosine was com-
pletely reduced: alas it was! The only conclusion left was that
the peak, which co-migrated with C18 sphingosine after cata-
lytic hydrogenation, was not C18 sphingosine, but another
long-chain base. This hypothesis lead to further analyses and
the discovery of branched-chain long-chain bases in the kidney
and tomy first paper published in Biochemistry (1). I then had a
pivotal conversation with Herb: he told me that I could either
look for more of these long-chain bases in other tissues or pur-
sue something totally different. It wasmy choice, and I chose to
pursue something different. I never forgot this conversation
because there is always a dilemma of where to go next in
research, especially after making a new discovery.
While I was engaged in my Ph. D. research and contemplat-
ing my future research, Herb became Vice Chancellor for aca-
demic affairs at Urbana and George Schroepfer kindly allowed
me to transfer to his group to work on my own project. I
thought that figuring out the in vitromechanism by which the
double bond in sphingosine arose, which was unknown at that
time, would be a nice and important project. After many
months of trying everything I could think of and getting
nowhere, I was desperate. In my desperation, I did a somewhat
irrational experiment, where I addedATP to a reactionmixture
with tritiated sphinganine (a saturated sphingosine base) on the
assumption that energy might be required for the double bond
formation. It was not, but I noticed that the radiolabel became
soluble in the aqueous layer of a water/chloroform/methanol
mixture and not as sphinganine in chloroform/methanol. This
led to the discovery of a crude sphinganine kinase, a Journal of
Biological Chemistry paper, and the conclusion of my Ph. D.
thesis (2).
Postdoctoral studies
With these results, I got the courage to tell Herb Carter and
George Schroepfer that I wanted to go toGene Kennedy’s lab at
HarvardMedical School towork as a postdoc on phospholipids.
Fortunately forme, theywere supportive, and after an interview
with Gene, I was accepted in his lab, provided I could get a
fellowship. I was in the U. S. on a student visa and could not
apply toNIHorNSF for fellowships. I ended up looking at small
foundations that would allow foreigners to apply. I discovered
the Jane Coffin Childs Memorial Fund for Medical Research
and applied, having no idea that it was rather prestigious! I was
asked for a final interview to visit Charles Huggins in Chicago.
Huggins was on the Board of the Fund and had received the
Figure 1. Structure of sphingosine.
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Nobel Prize for his work on prostate cancer. I did not know this
and George Schroepfer later told me he did not want to scare
me, but Huggins had a reputation of intimidating scientists,
both young and old. The interview took place in Huggins’ lab:
he was standing on one side of a lab bench, and I was sitting on
a lab stool on the other side. He asked his first question:What is
science? Without waiting for an answer, he asked the second
question: What is research? At some point, during one of my
answers, I said that I sometimes got emotional about my lab
work. He stoppedme and askedme sternly: “You get emotional
about your lab work?” I started to backtrack and clarified by
saying yes, but that I was also aware that this could have some
limitations. He then asked whether I had met Gene Kennedy. I
answered yes, andHuggins started his elegy about Kennedy and
at the end said that Gene also gets emotional about his work!
Lucky me, I had said the right words! I left the interview
exhausted but got the fellowship, which ended up being more
than generous (more about this later).
Gene Kennedy’s lab was small, around seven people. While
there, I made lifelong friends with Bill Dowhan (who has made
very important and novel contributions to the role of phospho-
lipids inmembranes andwrote a Reflections article in this jour-
nal recently), Chris Raetz (whose untimely passing was tragic
and whose friendship is thoroughly missed), Bill Wickner (a
world expert in protein translocation across membranes), and
toward the end ofmy stay, JimRothman (who received the 2013
Nobel Prize in Physiology and Medicine).
During those times, postdoctoral fellowships lasted for 2
years. At the end of my first year as a postdoctoral fellow, I had
accomplished absolutely nothing. My project was to purify
Escherichia coli cardiolipin synthase using a radiolabeling activ-
ity assay with CDP-diglyceride and radiolabeled phosphatidyl-
glycerol. This was then thought to be the pathway for biosyn-
thesis of cardiolipin (Fig. 2). I was unable to solubilize the
enzyme and do assays while the enzyme remained active. I felt
Gene thought my lack of ability was the cause for the slow
progress of the project. Having once seen a full list of the post-
docs who had been in his lab, half of which we had never heard
of, I feared that I was destined to join them, and I was pretty
discouraged. Fortunately, Gene let me test an alternative
hypothesis, namely that cardiolipinwas synthesized by the con-
densation of two phosphatidylglycerols, yielding cardiolipin
and free glycerol. I would have done this onmy own, but I could
not order radioactive substrates without Gene knowing. I syn-
thesized tritiated phosphatidyl glycerol and [32P]CDP-diglycer-
ide, showed that the latter was not a substrate, and showed that
both free glycerol and cardiolipin were reaction products. It
turns out that Joan Lusk in Gene Kennedy’s lab had previously
obtained in vivo evidence supporting this pathway: she had
found that, upon feeding radiolabeled glycerol to E. coli, some
of the starting product was converted to phosphatidylglycerol,
and after a lag, additional free glycerol and cardiolipin appeared
within the cell, consistent with the in vitro pathway we had
described. Fortunately for me, Gene decided to publish our
results in theProceedings of theNational Academy of Sciences of
the U.S.A. (PNAS) (3). At that time, if a National Academy
member (Gene) wanted to publish in PNAS, there was no fur-
ther required review of the manuscript!
While in Boston, I spent some of my time outside of lab
attending many, somewhat esoteric, classical music concerts.
During one such concert at the Old West Church in Boston,
which celebrated the 300-year anniversary of Heinrich Schütz’s
death, I met a wonderful woman. Her name was Lois. She later
became my wife, and we have been married ever since.
I decided to do a second, 2-year postdoc in Phil Robbins’ lab
atMIT. I applied for a 1-year extension ofmy JaneCoffinChilds
Memorial Fund for Medical Research Fellowship and was
advised by the director that while this was not unprecedented, I
had to convince the Board of Scientific Advisors that I deserved
this extra year more than new applicants who had never had a
fellowship. I still wince at this, but as luckwould have it, I had an
ally in Joan Lusk. Joan, as mentioned previously, had been a
former student inKennedy’s lab and hadmoved on to a postdoc
position in Salvador (Salva for short) Luria’s lab at MIT. Luria
happened to be on the Board of the Jane Coffin Childs Memo-
rial Fund for Medical Research, and Joan had told him about
our cardiolipin synthase results. I was able to get a third year of
funding!
During my stay in Phil Robbins’ lab at MIT, I studied the
relation of lipids of Sindbis virus, and those of the host cell
plasma membrane, and found them to be very similar (4). The
major emphasis of Phil’s labs was glycosylation of proteins, and
my stay made two major long-term impacts on my life: I
decided to work on glycosylation in my future, independent
scientific career, and I developed a lifelong friendship and
professional relationship with Phil, which lasted up to our
retirement.
Real job
St. Louis, MO
In 1973, there were few academic job openings. I started to
worry whetherGenewas recommendingme for these positions
andwhether I would be able to obtain one of them. Fortunately,
his secretary, Phyllis Elfman, who really ran Gene’s lab, told me
thatGenewasn’t gettingmany letters looking for job applicants.
Eventually, there was an opening in the Biochemistry
Department at St. Louis University School of Medicine, and
when Bob Olson, the Chairman, asked Gene for a letter of rec-
ommendation, Gene called him by phone. This made an enor-
mous difference, as it got me an interview. I later heard that for
three job openings, they got 400 applications! I got the job, but
before leavingMIT, I received a phone call fromSalva Luria.My
blood pressure immediately went up!
I had received money, for what amounted to approximately
half an NIH grant, from the Jane Coffin Childs Memorial Fund
for Medical Research to start up my independent laboratory.
Salva wanted to know whether I would return the unspent
money to the Fund if I received an NIH grant during the first
Figure 2. Structure of cardiolipin.
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year. With this money and the startup money from St. Louis
University, I was in good shape for some time, so I was happy to
tell Salva “yes.” It’s easy to be generous if you have money!
At St. Louis University, I was fortunate enough to get two
3-year RO1 grants within a short period of time: one on glyco-
sylation and one on sphingolipids. The former grant would last
for over 30 years without interruption, while I let the latter
expire after 6 years! I then started a second grant on sulfation
and phosphorylation of sugars in secreted proteins such as
casein, which lasted 20 years without interruption. My first
grant on glycosylation was focused on the existence of cell-
surface glycosyltransferases. Saul Roseman had postulated that
cell-surface glycosyltransferases, in conjunction with extracel-
lular nucleotide sugars, led to glycoconjugates being synthe-
sized on cell surfaces, where they were enriched in the cell and
thought to play important roles in cell–cell interactions.While
at MIT, my lab bench had been behind Bart Sefton, who was
also a postdoc andwho knew a lot about cell biology and cells in
tissue culture. Bart alwaysmentioned tome that removing cells
that had been grown in tissue culture from a monolayer for
biochemical experiments most likely caused severe injury to
these cells, if not death. If broken or dying cells were incubated
with nucleotide sugar, it would be difficult, if not impossible, to
do experiments with cultured cells, where one could ascribe
glycosylation to the cell surface, and not to other internal
organelles. Most, if not all, cell-surface glycosylation studies at
the time had removed cells grown in monolayer with trypsin,
EDTA, or even scraping. We determined that under all these
conditions of cell removal followed by mock incubations, the
great majority of cells had most likely died as they would not
re-adhere to tissue culture plates and grow. The control con-
sisted of removing cells from the monolayer with trypsin and
resuspending in tissue culture medium with serum, in which
case 80% of cells adhered to the plates and grew. So, clearly
one could not remove cells from monolayers for the experi-
ments we wanted to do. When we incubated cells grown in
monolayers with nucleotide sugars, in the presence of incuba-
tion buffers, we found that virtually all nucleotide sugars were
degraded, and free radioactive sugar was found in the incuba-
tion medium. A small amount of radioactive sugar was cova-
lently bound to cell surfaces, but a large amount of soluble
radioactive sugar was within the cells. Thus, we could not rule
out that free sugar, from nucleotide sugars, was entering cells,
subsequently being converted to nucleotide sugars, and then
acting as donors to glycanswithin cells in reactions catalyzed by
glycosyltransferases within cells. C. P. Leblond and his group
had recently obtained electron microscopic–autoradiographic
evidence for this internal (in theGolgi apparatus) glycosylation.
The problem for us was thatmany of the leading laboratories
in glycosylation were publishing papers in top journals on the
existence of cell-surface glycosyltransferases. We were new-
comers to the field! Fortunately for us, Ed Heath (then chair of
the Biochemistry Department at the University of Iowa) came
to the department to give a seminar, and when I showed him
our results, he gave me two important pieces of advice. Ed had
been a postdoc in Saul Roseman’s laboratory. He toldme that if
Saul isn’t working on this anymore, it means he is skeptical
about the whole theory. In addition, he suggested we not say
that surface glycosyltransferases do not exist, but instead say
the current evidence does not support the hypothesis.With this
advice, we submitted a paper to Biochemistry (5). One reviewer
thought it was fine, the second stated that somany papers could
not be wrong and recommended rejection, and fortunately, the
final referee recommended publication! With this I was able to
renew my RO1 grant.
Soon after that, I unexpectedly got a phone call from Saul
Roseman. I had seen Saul tear a speaker (who later became a
National Academy of Sciences member) to shreds at a FASEB
meeting inAtlantic City by asking him to summarize the theory
of Arrhenius plots, whichmany, at the time, were using to study
lipidmembrane fluidity! The first thing Saul said tome over the
phone was that he did not want to discuss cell integrity, but
“your results contradict your own hypothesis,” he said. “How?”
I asked, and he reiterated the finding that we had found some
radiolabeled sugar covalently attached to cell surfaces, which he
suggested supported his theory. When I replied that this was
most likely due to the free sugars within cells, which had been
converted to nucleotide sugars within cells, making them sub-
strates for internal glycosylation, he told me to forget about the
soluble radioactivity within cells. My answer was that I wanted
to be quantitative and to do so we had to take this into account.
Obviously, he was testingme andwe later became good friends!
According to my Chair, he even wrote me a positive letter of
recommendation for my promotion to Associate Professor
with tenure!
In the early 1970s, thanks to the pioneering studies byGeorge
Palade, Günter Blobel, and David Sabatini, it was established
that membrane and secreted proteins were synthesized on
membrane-bound polysomes, were then translocated into the
lumen of the endoplasmic reticulum, and thereafter, migrate via
vesicles to the Golgi apparatus. From there they go to the plasma
membrane or are secreted. It is in the lumen of the endoplasmic
reticulum where many proteins are initially glycosylated by
sugars, covalently linked to the lipid dolichol. Through the
work of C. P. Leblond’s group and others, it had also been
shown that in the Golgi apparatus lumen, many additional sug-
ars are added to these proteins, not by dolichol, but instead
directly by nucleotide sugars (Fig. 3). The latter are synthesized
in the cytosol andmust, therefore, reach the lumen of the Golgi
apparatus by what was then an unknown mechanism. We pos-
tulated that there were transporters for these nucleotide deriv-
atives in the Golgi apparatus membrane.
Together with David J. Carey, we decided to test whether we
could demonstrate in vitro transport of nucleotide sugars into
Golgi vesicles from rat liver. Before such experiments could be
done, we had to demonstrate that the vesicles we used were
sealed and of the same in vivo membrane topography Fortu-
nately, wewere able to prove both points. The first substrate we
tested was CMP-sialic acid, and we compared the behavior of
this nucleotide sugar with that of standard “penetrators” such
as deoxyglucose, which enters the Golgi apparatus passively,
and that of nonpenetrators such as inulin. We observed that
radioactivity from CMP-[3H]sialic acid entered the lumen of
the vesicles at a much faster rate than deoxyglucose and free
sialic acid. Additional results also further supported our
hypothesis: CMP-sialic acid did not enter vesicles derived from
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the endoplasmic reticulum, transport was saturable with a Km
in the 1–2 M range, and when we mixed commercially avail-
able CMP-[3H]sialic acid with [14C]CMP-sialic acid, synthe-
sized in the lab, the entire molecule appeared to enter as a unit.
We submitted this evidence to Cell (6), where it was accepted.
We were still worried about adsorption of nucleotide sugars
to vesicles, rather than transport into vesicles, although the evi-
dence argued strongly against adsorption.While no reviewer of
subsequent papers brought this up, it eventually came up dur-
ing a seminar I gave at Merck. During the seminar, Chris Raetz
(who was at Merck at that time), my good friend from Gene
Kennedy’s lab, promptly raised the question of adsorption. By
then, Juan Capasso, in our lab, in collaboration with Tom
Keenan, had demonstrated transport of ATP into the Golgi
apparatus, of rat mammary glands and showed that although
4,4-diisothiocyano-2,2-stilbenedisulfonic acid (DIDS) (a stil-
bene derivative and anion transport inhibitor) inhibited trans-
port of ATP, it did not inhibit transfer of phosphate from ATP
onto endogenous luminal Golgi acceptors such as casein. On
the other hand, EDTA, which inhibited transfer of phosphate
from ATP to casein and did not enter Golgi vesicles, did not
inhibit transport of ATP onto the lumen of Golgi vesicles and
subsequent transfer to casein. This was unequivocal proof that
transport of ATP into the Golgi lumenwas followed by transfer
of phosphate to lumenal casein, and by extrapolation, that
transfer of nucleotide sugars was followed by transfer of sugars
to endogenous protein and lipid acceptors (7). Luigi Puglielli, in
my lab, later purified this transporter to homogeneity. Subse-
quently Caroline Clairmont, also in my lab, demonstrated
transport of ATP into the endoplasmic reticulum and Eduardo
Guillen partially purified this transporter. Transport of nucle-
otide sugars such UDP-glucose and UDP-GlcNAc into the
endoplasmic reticulum of rats was shown by Mary Perez (8).
In earlier in vitro nucleotide sugar transport studies, we had
measured the internal volume within vesicles and concluded
that nucleotide sugars were concentrated within the lumen of
the vesicles 10–30–fold, compared with their concentration in
the reaction medium. If this was correct, then energy would be
required, but we knew that the assay did not require ATP or
another energy source in the reaction medium. The fact that
several ionophores had no effect on transport led us to hypoth-
esize that an antiport mechanismwas responsible for the uphill
transport of nucleotide sugars into the Golgi lumen. Together
with Juan Capasso (9), we showed that incubating vesicles with
[3H]GDP-fucose resulted in tritiated GMP accumulation in the
lumen. If we followed the above incubation with GDP-[14C]fu-
cose, we saw an exit of tritiated GMP from the lumen and cova-
lent attachment of 14C-radiolabeled fucose within the Golgi
apparatus lumen. This suggested that entry of nucleotide sugar
into the Golgi lumen, against a concentration gradient, was
coupled to the exit of the corresponding nucleosidemonophos-
phate. As a control, we used GDP-mannose, which did not
enter the lumen of Golgi vesicles, and determined that this exit
did not occur without entry of a structurally similar nucleotide
sugar. Previous studies had shown that the lumen of the endo-
plasmic reticulum and Golgi apparatus contained nucleoside
phosphatases of unknown function. Now, with our studies, it
became clear what they were for.
Could one obtain genetic evidence to support the existence
of Golgi nucleotide sugar transporters? Pamela Stanley, at the
Albert Einstein College of Medicine, and independently, Eve
Barak in Stu Kornfeld’s lab (at Washington University in St.
Louis), had characterized two Chinese hamster ovary cell lines
that were thought to be defective in the above transport system.
Both cell lines were defective in glycosylation: one lacked sialic
acid, and the other lacked galactose and sialic acid. Neither cell
line had a defect in glycosyltransferases, nor in nucleotide sugar
biosynthesis. Sue Deutscher, in my lab, grew liters of these
mutant and WT cells in tissue culture and isolated a crude
Golgi fraction with which she was able to measure transport of
CMP-sialic acid (10) and UDP-galactose (11). Both cell lines
were defective in transport of the above two substrates, and
importantly, the latter was not defective in transport of other
uridine nucleotide sugars, suggesting that there were individual
transporters for the different uridine-containing nucleotide
sugars and not a common one (9). As will be shown later, we
were very fortunate because this story became much more
complex in other biological systems.
We also knew that if we were going to eventually purify these
transporter proteins, we had to develop a reconstitution assay
with liposomes, which would enable us tomeasure transport in
vitro. While in my lab, Marcos Milla (12) developed such a
system and was able to show that the reconstituted systemwith
Golgimembrane proteins retained the transport characteristics
of the original Golgi vesicle system. Using this assay, Elisabet
Mandon and Luigi Puglielli, in a collaborative work with Anant
Menon’s group, later successfully purified several rat liverGolgi
nucleotide sugar transporters to homogeneity. Because such
transporters are in such low abundance, final purity had to be
confirmed by radioiodination of the proteins prior to SDS gel
electrophoresis (13, 14).
Figure 3. Schematic of a eukaryotic cell.Membrane and secreted proteins
are made on membrane-bound polysomes and translocated into the lumen
of the endoplasmic reticulum (ER). Many proteins undergo initial glycosyla-
tion in the lumen via dolichol sugars. Proteins thenmigrate via vesicles to the
Golgi apparatus. In the lumen of the Golgi apparatus, additional posttransla-
tional modifications occur catalyzed by different transferases and kinases.
Donors are nucleotide sugars, ATP, and PAPS, which are synthesized outside
the Golgi apparatus lumen and are transported via transporters shown in
Fig. 4.
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Our lab also spent considerable effort in the field of pro-
teoglycans. These are glycosylated proteins with covalently
linked amino sugars, such as uronic or iduronic acid. I never
completely understood why this was a different field from gly-
coproteins and glycolipids. Yes, the functions of proteoglycans
are very different from glycoproteins, but then again they share
major biosynthetic pathways. Through the work of Enrique
Brandan, Ariel Orellana, and Yasuhiro Hashimoto in my lab,
the pivotal enzymeheparan sulfateN-deacetylaseN-sulfotrans-
ferase was purified, cloned, and functionally expressed (15, 16)
in an erawhen thiswas very challenging for intrinsicmembrane
proteins. Later on, in collaboration with Stu Swiedler’s group,
we showed that the enzyme had the above dual activity, that it
functioned as a monomer in the Golgi membrane, and that its
active site was on the C terminus. Leny Toma demonstrated
that transport of nucleotide sugars regulates the biosynthesis of
proteoglycans (17).
The sulfate donor of proteoglycans is PAPS,2 which had been
discovered by Phil Robbins while he was a postdoc in Fritz Lip-
mann’s laboratory. I remember after a talk I gave at a Gordon
Conference, Phil suggested I look into transport of the above
nucleotide into the Golgi apparatus. I had not heard of PAPS
before, but we determined that transport of such a molecule
into theGolgi lumen occurred, and later ElisabetMandon puri-
fied this transporter (8).
Transport of other nucleotide sugars that are building blocks
for proteoglycans such as UDP-GlcA, UDP-xylose, and UDP-
glucose into the Golgi apparatus was demonstrated by Mary
Perez, Elisabet Mandon, and Naziha Nuwayhid, the latter in
collaboration with Ed Conrad’s group (8). A summary of nucle-
otide sugar transporters in different organisms is shown in
Fig. 4.
Worcester, MA
In 1987, I moved my lab to the University of Massachusetts
Medical School in Worcester, a city 40 miles west of Boston.
Claudia Abeijon, who had been a graduate student of mine and
stayed on as a postdoc, went to Phil Robbins’ lab atMIT to learn
yeast genetics, a subject my lab was not familiar with, but Phil’s
was. The addition of yeast as a model system proved to have
major advantages for us.With its “awesome” power of genetics,
it allowed us to unequivocally prove the above described anti-
port system. As will be discussed below, we were also able to
clone the first nucleotide sugar transporter and develop a sim-
ple assay for putative transporters in non-yeast model systems.
Shortly after arriving at UMass, one of my NIH grants was
awarded MERIT status. What a wonderful feeling! 10 years of
not having to go through study section! While this made me
more than happy, I found out that when I moved to UMass,
their fringe benefits rate, charged to NIH grants, were much
higher than those in St. Louis. ThenewNIHgrant budget onmy
MERIT award did not reflect this increase in fringe benefits.
Even with the help of my NIGMS program director, Lee van
Lenten, I could not get the substantial extra money for the new
grant because it was considered a supplement.When I received
the MERIT award, Lee suggested I write to then NIGMS direc-
tor Ruth Kirschstein, who I had met earlier in my career. How
do I get Kirschstein’s attention knowing that she was busy and
received many letters every day? I started my letter by stating
that I was both honored and disappointed to receivemyMERIT
award and then explained my situation regarding the fringe
benefits! Voila! In a few days, I received the adjustment of my
grant. The lesson, which I shared from then on with my stu-
dents and postdocs, was that if the first three lines in a petition
letter do not have an impact on the receiver, you have lost! The
same applied in certain sections of grant writing, and it never
failed!
We had previously obtained in vitro evidence that transport
of nucleotide sugars into the Golgi apparatus lumen was ener-
getically uphill, and had postulated that the entry was coupled
with exit from the lumen into the cytosol, down a concentration
gradient of the corresponding nucleoside monophosphate (7).
This compound, in turn, would arise fromGolgi luminal nucle-
oside diphosphatases acting upon nucleoside diphosphates,
which are the reaction products following transfer of sugars
from nucleotide sugars to endogenous acceptors in reactions
catalyzed by glycosyltransferases. Because in Saccharomyces
cerevisiae the major sugar donor is GDP-mannose, we postu-
lated the existence of aGolgi luminalGDPase. In a collaborative
study with Phil Robbins’ group, we characterized, purified, and
cloned a S. cerevisiae Golgi luminal GDPase and showed that
deletion of this gene resulted in shorter mannan chains on
Golgi proteins and lipids (8). This provided unequivocal evi-
dence for the antiporter system.
I remember the dayClaudiaAbeijon showedme apaper from
Clinton Ballou’s lab in which they described a mutant of
Kluyveromyces lactis, which lacked terminal GlcNAc in its
mannan chains, but was not defective in itsN-acetylglucosami-
nyltransferase, nor in synthesis of UDP-GlcNAc. The authors
postulated a possible compartmentalization defect. Claudia
went on to show that indeed the mutation caused a defect in
transport of UDP-GlcNAc into theGolgi lumen ofK. lactis. She
then was successful in cloning the gene that corrected the
mutant phenotype. I distinctly remember the day she came and
showed me the putative protein profile of the gene product. It
2 The abbreviations used are: PAPS, 3-phosphoadenyl-5-phosphosulfate;
LAD II, leukocyte adhesion deficiency II; GlcA, glucuronic acid.
Figure 4. Transport activities of nucleotide sugars, ATP, and PAPS in the
Golgi apparatus membrane of different organisms. SA, sialic acid.
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was a polytopic protein that traverses the membrane many
times (18). We were elated! As usually happens with important
discoveries, a short time later Rita Gerardy-Schahn’s lab was
successful in cloning the mammalian CMP-sialic acid trans-
porter, and thereafter, several groups cloned other nucleotide
sugar transporters.
Eduardo Guillen, in my lab, undertook an ambitious project
to determine whether one could correct the K. lactismutation
with the corresponding mammalian gene. There were many
potential pitfalls with this project, including the poor quality of
the mammalian cDNA library, lack of mammalian transporter
gene expression in yeast, improper protein targeting to the
Golgi membrane, and/or inability to correct cell-surface
expression of GlcNAc in K. lactis. Fortunately, all of this
worked, and we had not only cloned the corresponding mam-
malian transporter gene in a heterologous system, but it made
us optimistic that this approach would work in other heterolo-
gous systems (19). This would prove invaluable in our next
major enterprise in which we studied the role of nucleotide
sugar transporters in multicellular systems such asCaenorhab-
ditis elegans.
Boston, MA
In 1998, I became Professor and Founding Chair of the
Department of Molecular and Cell Biology at the Henry M.
Goldman School of Dental Medicine of Boston University.
Spencer Frankl, the Dean, wanted to diversify the NIH research
portfolio of the School. I accepted the offer with two caveats:
that I could hire diverse faculty in basic sciences and that Phil
Robbins would take early retirement from MIT and join me in
establishing this new department. We were fortunate in hiring
several outstanding faculty members who are world experts in
their respective fields: Miklos Sahin-Toth in pancreatitis, John
Samuelson in protozoan parasites, and David Levin in stress
signaling and cell wall biogenesis in fungi. We also started two
seminar series: the first invited outside experts in diverse areas
of biology, and the second invited scientists and research clini-
cians from Boston University. While our aim with the latter
series was to become acquainted with ongoing research at Bos-
ton University, we also became aware that this gave an oppor-
tunity for the faculty of Boston University to get to know our
department. Thus, we invited faculty from theDental andMed-
ical Schools, the College of Engineering, and the College of Arts
and Sciences. These seminars became the department’s win-
dow to the university and a chance for the university faculty to
get to know us. Our faculty also became participants in the
Bioinformatics program, administered by the College of Engi-
neering, and developed a course in molecular genetics for first-
year dental students.
My lab’s expansion intoC. elegans as amodel system to study
nucleotide sugar transporters was fortuitous and proved to be a
goldmine. ToryHerman in BobHorvitz’s (Nobel Prize in Phys-
iology and Medicine in 2002) lab at MIT had found eight com-
plementation groups that corrected the squashed vulva pheno-
type of C. elegans mutants she had generated. Mutant SQV-7
appeared to encode a nucleotide sugar transporter. The litera-
ture was full of putative transporters for these substrates, yet
they had no function that had been established experimentally!
We had previously found that the primary amino acid sequence
of these transporter proteins could not predict their substrate
specificity and that two transporters for UDP-GlcNAc, one
from K. lactis and one from canines, had very different amino
acid sequences, and yet, had the same substrate specificity. This
was true even when the latter was expressed in a heterologous
system such as K. lactis, where we had shown it complemented
the K. lactismutant phenotype!
The only way to establish the function of a putative nucleo-
tide sugar transporter was to directly measure transport! Patri-
cia Berninsone, in my lab, first attempted to express SQV-7 in
S. cerevisiae without success. We wondered whether any per-
son had ever attempted this (a C. elegans gene in yeast). Fortu-
nately, it proved to be a technical problem, and she eventually
succeeded in expression. She then isolated Golgi vesicles from
the transformed yeast and assayed every radiolabeled nucleo-
tide sugar we could get our hands on for transport. As stated
previously, S. cerevisiae has only two endogenous transporters,
those forGDP-mannose andUDP-glucose. Initially, after trans-
formation, we were shocked to find transport signals for UDP-
Gal, UDP-GlcNAc, andUDP-GlcA!We had never seen a trans-
porter formore than one substrate, and this specificity had been
one of our landmark biochemical signals, which had given us
confidence in the reliability of the in vitro transport assay! For-
tunately, SQV-7 did not appear to transport UDP-GalNAc or
other nucleotide sugars, again suggesting substrate specificity,
including carbohydrate anomers. The two mutants isolated by
Tory Herman were defective in transport of the three above
substrates (UDP-Gal, UDP-GlcNAc, and UDP-GlcA) to differ-
ent extents, but transport of the other nucleotide sugars
appeared to be normal. This reassured us a bit. If the trans-
porter could transport three substrates, then the simplest
model would be for transport among substrates to be compet-
itive. Fortunately, this turned out to be the case (20).
Our studies of nucleotide sugar transporters in C. elegans
also led to the discoveries of two additional important novel
concepts. In one case, Carolina Caffaro and Patricia Bernin-
sone, determined that a transporter for UDP-GlcNAc and
UDP-Gal transported both substrates in a simultaneous and
independentmanner. Furthermore, Carolina constructed dele-
tionmutants and found that they transported one substrate, but
not the other, strongly suggesting that the transporter protein
has two different substrate-binding sites. This was a distinct
transport model from that found in studies with the SQV-7
mutants, where transport of substrates was competitive (21).
We also found, inC. elegans, that individual nucleotide sugar
transporters were tissue-specific. This represented an addi-
tional and important new concept regarding the genetic redun-
dancy of nucleotide sugar transporters and tissue development.
This discoverywasmade byCarolinaCaffaro andPatricia Bern-
insone. A C. elegans double mutant in two nucleotide sugar
transporters, both of which shared one substrate and partial
overlapping tissue specificity, showed a different phenotype
than each individual mutant (22). Important studies on the
structure of glycoconjugates in C. elegans were done by John
Cipollo, in collaboration with Cathy Costello’s group (23). In
retrospect, we had been extremely fortunate in our earlier bio-
chemical studies on transporters by initially finding that trans-
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porters were highly substrate-specific, something that the bio-
chemical community found easy to accept.
With the characterization of nucleotide sugar transporter
mutants in yeast and Chinese hamster ovary cells, we began to
think early on about the possibility of human genetic diseases
involving nucleotide sugar transporters. However, we also
thought that such diseases might be very pleiotropic, as many
glycoproteins might be affected, and we also suspected the dis-
eases to have a high likelihood of being lethal. Thus, we never
gave too much thought to finding such diseases, even if they
were nonlethal.
Major credit for discovering such diseases goes toAmos Etzi-
oni and colleagues at the Medical Center in Haifa, Israel. In
1992, twounrelatedArab boys living in Israel, then 3 and 5 years
old, each the offspring of a consanguineous mating, came to
Etzioni’s clinic. Both showed severe psychomotor and mental
retardation together with a flat face and depressed nasal bridge.
They also presented recurrent infections with marked neutro-
philia and periodontitis. The children had a rare blood pheno-
type called Bombay, wherein the red blood cells express a non-
fucosylated variant of the H antigen. Also missing from the red
blood cells were Lewis blood group antigens such as sialyl Lewis
X, an important ligand for selectins on leukocyte surfaces.
Fucosyltransferases, catalyzing the addition of fucose via differ-
ent linkages to other sugars, were normal in the twoboys, aswas
the biosynthesis of GDP-fucose, the universal fucose donor to
macromolecules. The disease was named leukocyte adhesion
deficiency II (LAD II). LAD II was distinct from LAD I, which
arises from mutations in the gene encoding the integrin 2
subunit. In addition, the infections in LAD I are more serious,
but patients do not suffer other symptoms, includingmental or
growth retardation.
Etzioni, in collaborationwithMichaela Tonetti’s group at the
University of Genoa, Italy, immortalized lymphoblasts from
one of the above children, as well as those from both parents
and a control. Laura Sturla, from Tonetti’s lab, came to our lab,
and together, we isolated Golgi vesicles from the child’s im-
mortalized lymphoblasts, the mother, the father, and a control.
We then performed transport assays using GDP-fucose. We
found that the child had approximately one-third of theVmax of
that of the parents and normal control. Transport of other
nucleotide sugars was normal in all samples (24).
Later, von Figura’s group cloned theGDP-fucose transporter
gene and established that the above child had a point mutation
in the coding region. When Carolina Caffaro expressed the
mutated and WT protein transporters and reconstituted them
into liposomes, she found that the mutation caused a partial
loss of GDP-fucose transport. At the same time, ThorstenMar-
quardt at the University of Muenster had also identified
another child, of Turkish origin, with a defect in GDP-fucose
transport. Since then, other examples of defects in nucleotide
sugar transport in children have also been described.
Meeting two of the above named children proved to be a
memorable occasion in my scientific life career as a basic
research scientist. At a meeting in Germany, I met the Turkish
child and the above named Arab-Israeli child at his home in
Israel. At that time, the latter was about 17 years old. While
mentally challenged, he went to a specialized school and could
understand the love of his family and several siblings, who for-
tunately were all normal. Although the mutation was recessive,
each sibling had a 25% chance of having the disease. Before
meeting these two children, I talked to one of our human genet-
icists at Boston Medical Center. He gave me two pieces of
advice: do not mention prenatal diagnosis unless asked, and do
notmention gene therapy because for these children, it is unre-
alistic. I will never forget meeting these children and their lov-
ing parents as it brought our basic science into “real world.”
Some of the students and postdocs in the lab had prior expe-
rience with protozoan parasites. We thought that studying
nucleotide sugar transporter in these organisms might give us
novel biological and biochemical insights. Studies that showed
the occurrence of nucleotide sugar transporters in protozoan
parasites established additional new concepts. In collaboration
with John Samuelson’s group, Luis Bredeston of my lab found
endoplasmic reticulum and Golgi apparatus functions in these
organisms (25), and in collaborationwith JayBangs andBarbara
Burleigh’s groups, Li Liu and Yu Xin Xu of my lab described a
nucleotide sugar transporter that transports both purine and
pyrimidine substrates in Trypanosoma brucei, something we
had never seen in any organism before (26). Together with John
Boothroyd’s group, CarolinaCaffaro showed that a deletion of a
transporter gene in Toxoplasma gondii contributed to changes
in infectivity (27).
In 2013, I received the Rosalind Kornfeld Lifetime Achieve-
ment Award from the Society for Glycobiology (Fig. 5). This
was a particular honor for me because Rosalind had been the
vice chair of the 1989 Gordon Research Conference on Glyco-
proteins andGlycolipids, which I had chaired. Rosalindwas not
only an outstanding scientist, but she was an incredibly kind
Figure 5. Photo of the author, 2013 ASBMB archives.
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and caring human being. She, together with Stuart Kornfeld
and Jacques Baenziger, had been instrumental in helping me
arrange the scientific program for that conference.
One year later, I decided to close the lab, retire, and move
with my wife Lois to Southern California. I still travel, once a
year, for 2 weeks, to the Universidad Andres Bello in Santiago,
Chile, where I am a professor. While there, I teach a rigorous
seminar course for Ph. D. students on critical thinking. It deals
with classical experiments in biochemistry, based on the Jour-
nal of Biological Chemistry Classics series, that led to key con-
cepts such as DNA replication, discoveries of cAMP, growth
factors, tRNA, phospholipid pathways, and feedback inhibition,
among others (28). I tell the students that if they learn to think
in science as these great scientists did, then they are assured to
become first-rate scientists. I also help friends and friends of
friends with their grant proposals.
In looking back, I feel most fortunate to have had very tal-
ented graduate students and postdocs who enabled me to have
a wonderful scientific career. Fortunately, most of them are still
in science, and many have made very important contributions
to their own fields of study.
Unfulfilled dreams
Wewould have liked to do some structural studies on nucle-
otide sugar transporters. Unfortunately, we never succeeded in
obtaining sufficient amounts of protein for such studies. While
I was working on this article, however, an excellent paper was
recently published in Nature by Parker and Newstead (29) in
which they obtained the first crystal structure of a Golgi nucle-
otide sugar transporter from S. cerevisiae that transports GDP-
mannose. This outstanding study also includes biochemical
studies confirming the antiporter hypothesis and is hopefully
only the first of many structural studies of these transporters.
Important and interesting structural studies on these pro-
teins should include those of multisubstrate transporters,
including those with multiple competitive substrates and those
of independent and simultaneous substrates.
Cloning and deletion studies of the ATP transporters of the
Golgi apparatus and endoplasmic reticulum, which from
reconstitution studies must have structural differences, should
yield important results of additional functions of these proteins.
There should be diseases affecting the luminal Golgi and
endoplasmic reticulum nucleoside diphosphatases, although
their phenotypeswillmost likely be pleiotropic, such as those of
nucleotide sugar transporters.
Obviously there are many important and exciting projects to
be done! I wish I hadmore time, but I am sure younger scientists
will explore them.
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